Lucid Diagnostics Inc
NASDAQ:LUCD
Intrinsic Value
Lucid Diagnostics, Inc. develops medical testing devices. [ Read More ]
The intrinsic value of one LUCD stock under the Base Case scenario is 2.6245 USD. Compared to the current market price of 0.7965 USD, Lucid Diagnostics Inc is Undervalued by 70%.
Valuation Backtest
Lucid Diagnostics Inc
Run backtest to discover the historical profit from buying and selling LUCD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Lucid Diagnostics Inc
Current Assets | 22.1m |
Cash & Short-Term Investments | 18.9m |
Receivables | 45k |
Other Current Assets | 3.1m |
Non-Current Assets | 5.2m |
PP&E | 2.6m |
Intangibles | 1.4m |
Other Non-Current Assets | 1.1m |
Current Liabilities | 29.4m |
Accounts Payable | 1.1m |
Accrued Liabilities | 4.9m |
Short-Term Debt | 23.3m |
Non-Current Liabilities | 199k |
Other Non-Current Liabilities | 199k |
Earnings Waterfall
Lucid Diagnostics Inc
Revenue
|
2.4m
USD
|
Cost of Revenue
|
-6m
USD
|
Gross Profit
|
-3.6m
USD
|
Operating Expenses
|
-44.9m
USD
|
Operating Income
|
-48.5m
USD
|
Other Expenses
|
-4.2m
USD
|
Net Income
|
-52.7m
USD
|
Free Cash Flow Analysis
Lucid Diagnostics Inc
What is Free Cash Flow?
LUCD Profitability Score
Profitability Due Diligence
Lucid Diagnostics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Lucid Diagnostics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
LUCD Solvency Score
Solvency Due Diligence
Lucid Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Lucid Diagnostics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LUCD Price Targets Summary
Lucid Diagnostics Inc
According to Wall Street analysts, the average 1-year price target for LUCD is 3.91 USD with a low forecast of 2.525 USD and a high forecast of 8.4 USD.
Ownership
LUCD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LUCD Price
Lucid Diagnostics Inc
Average Annual Return | -64.46% |
Standard Deviation of Annual Returns | 12.75% |
Max Drawdown | -93% |
Market Capitalization | 38.2m USD |
Shares Outstanding | 47 999 100 |
Percentage of Shares Shorted | 2.92% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
Contact
IPO
Employees
Officers
The intrinsic value of one LUCD stock under the Base Case scenario is 2.6245 USD.
Compared to the current market price of 0.7965 USD, Lucid Diagnostics Inc is Undervalued by 70%.